Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
45 studies found for:    "von Willebrand disease"
Show Display Options
Rank Status Study
21 Completed Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
Condition: Von Willebrand Disease
Intervention: Biological: Recombinant von Willebrand Factor (rVWF)
22 Completed A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.
Condition: vonWillebrand's Disease
Interventions: Biological: Optivate® (Human Coagulation Factor VIII);   Biological: Haemate P® (Human Coagulation Factor VIII)
23 Completed Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
Conditions: Von Willebrand Disease;   Blood Coagulation Disorders;   Blood Platelet Disorders;   Hematologic Disease
Intervention: Drug: Blood coagulation Factor VIII and vWF, human
24 Recruiting Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Condition: Von Willebrand Disease
Intervention: Drug: plasma-derived FVIII/VWF concentrate Fanhdi
25 Completed
Has Results
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
Condition: Von Willebrand Disease
Interventions: Biological: Recombinant von Willebrand factor (rVWF);   Drug: Placebo;   Biological: Recombinant factor VIIII (rFVIII)
26 Completed The Von Willebrand Disease (VWD) International Prophylaxis Study
Condition: Von Willebrand Disease
Intervention: Drug: VWF/FVIII products
27 Completed Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
Condition: Von Willebrand's Disease
Intervention: Drug: von Willebrand factor
28 Recruiting Willebrand International Non-interventional Global Surveillance
Condition: Von Willebrand Disease
29 Completed
Has Results
Efficacy and Safety of IL-11 in DDAVP Unresponsive
Conditions: Hemophilia A;   Von Willebrand Disease
Intervention: Biological: Neumega (Oprelvekin, Interleukin 11, IL-11)
30 Recruiting Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
Condition: Von Willebrand Disease
Intervention: Biological: Alphanate SD/HT
31 Not yet recruiting Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
Condition: Von Willebrand Disease
Intervention: Other: Non interventional study
32 Not yet recruiting BAX 111 rVWF in Pediatrics
Condition: Von Willebrand Disease
Interventions: Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
33 Terminated Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
Condition: Von Willebrand Disease
34 Active, not recruiting
Has Results
Type 3 Von Willebrand International Registries Inhibitor Prospective Study
Condition: Type 3 Von Willebrand's Disease
35 Completed Acquired Von Willebrand Syndrome in Severe Aortic Stenosis
Conditions: Bleeding;   Von Willebrand Disease;   Aortic Stenosis
36 Completed A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)
Condition: Von Willebrand Disease
37 Completed Treatment and Management of Women With Bleeding Disorders
Conditions: Menorrhagia;   Blood Coagulation Disorders;   Blood Platelet Disorders;   Von Willebrand Disease;   Hematologic Disease
Interventions: Drug: Tranexamic Acid;   Drug: Desmopressin Acetate
38 Completed ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
Conditions: Purpura, Thrombotic Thrombocytopenic;   Von Willebrand Disease Type-2b
Intervention: Drug: ARC1779
39 Completed The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders
Conditions: vonWillebrand Disease;   Hemophilia;   Platelet Coagulation Disorders
Intervention: Drug: Cyclokapron
40 Completed A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
Condition: Von Willebrand Disease
Intervention: Biological: Optivate® (Human Coagulation Factor VIII)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-45) Show next page of results    Last Page
Indicates status has not been verified in more than two years